Provided by Tiger Fintech (Singapore) Pte. Ltd.

Prime Medicine, Inc.

2.17
+0.17008.50%
Volume:753.12K
Turnover:1.64M
Market Cap:277.03M
PE:-1.31
High:2.30
Open:2.05
Low:1.99
Close:2.00
Loading ...

Company Profile

Company Name:
Prime Medicine, Inc.
Exchange:
NASDAQ
Establishment Date:
2019
Employees:
214
Office Location:
21 Erie Street,Cambridge,Massachusetts,United States
Zip Code:
02139
Fax:
- -
Introduction:
Prime Medicine, Inc., a biotechnology company, delivers genetic therapies to address diseases by deploying gene editing technology. The company offers Prime Editors with a Prime Editor protein, comprising a fusion between a Cas protein and a reverse transcriptase enzyme; and a pegRNA, which targets the Prime Editor to a specific genomic location and provides a template for making the desired edit to the target DNA sequence. It has a research collaboration with Cimeio Therapeutics to develop Prime Edited Shielded-Cell & Immunotherapy Pairs for genetic diseases, acute myeloid leukemia, and myelodysplastic syndrome. Prime Medicine, Inc. was incorporated in 2019 and is based in Cambridge, Massachusetts.

Directors

Name
Position
Keith Gottesdiener
President, Chief Executive Officer and Director
David Schenkein
Director
Kaye Foster
Director
Michael Kelly
Director
Robert Taylor NELSEN
Director
Thomas Cahill
Director
Wendy Chung
Director

Shareholders

Name
Position
Keith Gottesdiener
President, Chief Executive Officer and Director
Carman Alenson
Interim Chief Financial Officer and Chief Accounting Officer
Meredith Goldwasser
Senior Vice President, Strategy and Corporate Operations
Andrew Anzalone
Senior Scientist II, Head of Prime Editing Platform
Ann Lee
Chief Technical Officer
Jeremy Duffield
Chief Scientific Officer
Richard Brudnick
Chief Business Officer